Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.ipca.com | |
Market Cap | 21,596.57 Cr. | |
Enterprise Value(EV) | 21,407.68 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 24.21 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 35.15 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 33.61 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 228.11 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 3.73 | Calculated using Price: 851.00 |
Dividend Yield | 0.47 | Period Ending 2022-03 |
No. of Shares Subscribed | 25.37 Cr. | 253,704,218 Shares |
FaceValue | 1 | |
Company Profile | ||
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. Ipca Laboratories is one of the largest suppliers of these APIs worldwide with manufacturing leadership in many APIs globally. It has various APIs and formulations manufacturing facility across the globe. The company has leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India |
1 Day |
|
-1.83% |
1 Week |
|
-1.58% |
1 Month |
|
-0.92% |
3 Month |
|
-8.55% |
6 Month |
|
-14.15% |
1 Year |
|
-15.79% |
2 Year |
|
-12.76% |
5 Year |
|
+198.20% |
10 Year |
|
+238.47% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 27.22 | 12.43 | 4.31 | 8.60 | 9.47 | 15.28 | 18.15 | 27.63 | 17.87 | |
Return on Capital Employed (%) | 27.92 | 13.78 | 4.82 | 9.44 | 9.94 | 16.53 | 19.92 | 30.92 | 20.41 | |
Return on Assets (%) | 16.19 | 7.38 | 2.50 | 5.17 | 6.03 | 10.25 | 12.47 | 20.29 | 13.30 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 1,960 | 2,208 | 2,259 | 2,455 | 2,689 | 3,122 | 3,627 | 4,702 | 5,492 | 5,778 | |
Non Curr. Liab. | 459 | 700 | 663 | 548 | 419 | 313 | 290 | 190 | 602 | 652 | |
Curr. Liab. | 791 | 904 | 970 | 956 | 1,008 | 1,098 | 1,326 | 1,161 | 1,466 | 1,385 | |
Minority Int. | 16 | 14 | 15 | 77 | 81 | ||||||
Equity & Liab. | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 7,896 | |
Non Curr. Assets | 1,609 | 2,198 | 2,270 | 2,218 | 2,170 | 2,171 | 2,402 | 2,629 | 3,180 | 3,342 | |
Curr. Assets | 1,601 | 1,614 | 1,622 | 1,742 | 1,945 | 2,378 | 2,856 | 3,437 | 4,457 | 4,554 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 7,896 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 3,282 | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 5,906 | |
Other Income | 52 | 59 | 41 | 55 | 58 | 75 | 87 | 129 | 122 | 86 | |
Total Income | 3,334 | 3,203 | 2,908 | 3,211 | 3,316 | 3,820 | 4,706 | 5,524 | 5,918 | 5,992 | |
Total Expenditure | -2,570 | -2,630 | -2,593 | -2,741 | -2,816 | -3,067 | -3,729 | -3,914 | -4,539 | -4,849 | |
PBIDT | 764 | 573 | 314 | 470 | 500 | 753 | 977 | 1,610 | 1,379 | 1,143 | |
Interest | -30 | -32 | -35 | -27 | -28 | -22 | -20 | -12 | -11 | -21 | |
Depreciation | -103 | -180 | -163 | -173 | -178 | -182 | -211 | -209 | -232 | -245 | |
Taxation | -152 | -102 | -20 | -68 | -51 | -104 | -135 | -240 | -225 | -237 | |
Exceptional Items | |||||||||||
PAT | 478 | 259 | 96 | 203 | 244 | 444 | 611 | 1,149 | 911 | 639 | |
Minority Interest | 3 | 3 | -1 | -6 | -8 | ||||||
Share Associate | 0 | -5 | -3 | -8 | -4 | -2 | -8 | -8 | -21 | -18 | |
Other Related Items | |||||||||||
Consolidated Net Profit | 479 | 254 | 93 | 195 | 239 | 446 | 606 | 1,140 | 884 | 614 | |
Adjusted EPS | 19 | 10 | 4 | 8 | 9 | 18 | 24 | 45 | 35 | 20 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 389 | 522 | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | |
Cash Fr. Inv. | -260 | -369 | -689 | -218 | -149 | -135 | -165 | -510 | -521 | -855 | |
Cash Fr. Finan. | -83 | -136 | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | |
Net Change | 46 | 17 | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 428 | |
Cash & Cash Eqvt | 57 | 74 | 104 | 169 | 143 | 218 | 371 | 295 | 559 | 991 |
Fri, 20 Jan 2023
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The 3Rd Quarter And Nine Months Ended 31St December 2022. IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the 3rd quarter and nine months ended 31st December 2022. |
Fri, 20 Jan 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper advertisement published in Business Standard and Nav Shakti regarding petition for sanction of Scheme of Amalgamation of Ramdev Chemical Pvt Ltd. and Tonira Exports Ltd. Companys wholly owned subsidiaries with the Company. |
Wed, 11 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022 |
Wed, 25 Jan 2023 |
|
|
|
|
|